Cancer BiologyThe EMBO JournalPeer-reviewed
Pharmacological CDK4/6 inhibitors promote senescence-associated lysosomal alterations and enhance sensitivity to lysosomotropic agents in breast cancer
Jamil Nehme, Sjors Maassen, Sara Bravaccini…·Marco Demaria
This study shows CDK4/6 inhibitors induce senescence-like changes in breast cancer cells, increasing their sensitivity to lysosomotropic agents, and suggests sequential treatment could improve therapy efficacy.
19 citationstop 2%